Exenatide

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Exenatide For Reducing the Reinforcing Effects of Cocaine

Diabetes Islet Preservation Immune Treatment

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Impact of Exenatide on Sleep Duration

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

Effects of Exenatide on Motor Function and the Brain

Exenatide Treatment in Parkinson's Disease

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.

GLP Analogs for Diabetes in Wolfram Syndrome Patients